Satraplatin for second-line treatment of hormone-refractory prostate cancer - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Satraplatin for second-line treatment of hormone-refractory prostate cancer - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2004
Authors' objectives
To summarise the currently available evidence on satraplatin for second-line treatment of hormone-refractory prostate cancer.
Authors' conclusions
Satraplatin, an orally-active platinum compound, is in phase III clinical trials as a second-line treatment for men with hormone-refractory prostate cancer (HRPC) who no longer respond or are refractory to first-line chemotherapy. Results of a preliminary phase III trial of satraplatin in combination with prednisone versus prednisone alone as first-line chemotherapy in HRPC has been reported in abstract form. Treatment with satraplatin significantly lengthened time to progression (5.2 months versus 2.5 months). At 6 months, 41% of patients treated in the satraplatin arm were progression free versus 22% of patients in the control arm.
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk